AU2017220184B2 - Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist - Google Patents

Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist Download PDF

Info

Publication number
AU2017220184B2
AU2017220184B2 AU2017220184A AU2017220184A AU2017220184B2 AU 2017220184 B2 AU2017220184 B2 AU 2017220184B2 AU 2017220184 A AU2017220184 A AU 2017220184A AU 2017220184 A AU2017220184 A AU 2017220184A AU 2017220184 B2 AU2017220184 B2 AU 2017220184B2
Authority
AU
Australia
Prior art keywords
vaccine
antagonist
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017220184A
Other languages
English (en)
Other versions
AU2017220184A1 (en
Inventor
Robert Evans
Neil Graham
Andrew J. Murphy
Lisa Purcell Ngambo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58192407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017220184(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2017220184A1 publication Critical patent/AU2017220184A1/en
Application granted granted Critical
Publication of AU2017220184B2 publication Critical patent/AU2017220184B2/en
Priority to AU2024204962A priority Critical patent/AU2024204962A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1225—Gram-negative bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017220184A 2016-02-19 2017-02-17 Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist Active AU2017220184B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024204962A AU2024204962A1 (en) 2016-02-19 2024-07-18 Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662297257P 2016-02-19 2016-02-19
US62/297,257 2016-02-19
US201662409936P 2016-10-19 2016-10-19
US62/409,936 2016-10-19
PCT/US2017/018487 WO2017143270A1 (en) 2016-02-19 2017-02-17 Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024204962A Division AU2024204962A1 (en) 2016-02-19 2024-07-18 Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist

Publications (2)

Publication Number Publication Date
AU2017220184A1 AU2017220184A1 (en) 2018-09-13
AU2017220184B2 true AU2017220184B2 (en) 2024-04-18

Family

ID=58192407

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017220184A Active AU2017220184B2 (en) 2016-02-19 2017-02-17 Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
AU2024204962A Pending AU2024204962A1 (en) 2016-02-19 2024-07-18 Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024204962A Pending AU2024204962A1 (en) 2016-02-19 2024-07-18 Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist

Country Status (17)

Country Link
US (3) US10314904B2 (cg-RX-API-DMAC10.html)
EP (2) EP3416685B1 (cg-RX-API-DMAC10.html)
JP (3) JP7597500B2 (cg-RX-API-DMAC10.html)
KR (1) KR102868264B1 (cg-RX-API-DMAC10.html)
CN (1) CN109069625A (cg-RX-API-DMAC10.html)
AU (2) AU2017220184B2 (cg-RX-API-DMAC10.html)
CA (1) CA3014202A1 (cg-RX-API-DMAC10.html)
ES (1) ES2983475T3 (cg-RX-API-DMAC10.html)
HU (1) HUE067673T2 (cg-RX-API-DMAC10.html)
IL (1) IL261025A (cg-RX-API-DMAC10.html)
MA (1) MA44238B1 (cg-RX-API-DMAC10.html)
MX (2) MX2018009990A (cg-RX-API-DMAC10.html)
PL (1) PL3416685T3 (cg-RX-API-DMAC10.html)
PT (1) PT3416685T (cg-RX-API-DMAC10.html)
RU (1) RU2753869C2 (cg-RX-API-DMAC10.html)
WO (1) WO2017143270A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201805295B (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
EP3454878A4 (en) * 2016-05-10 2020-07-29 Hennepin Healthcare Research Institute CYTOKINE IMMUNOMODULATORS AND SIGNALING METHODS
KR102872485B1 (ko) * 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
US11034768B2 (en) 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
MA55204A (fr) * 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CA3161037A1 (en) 2019-12-09 2021-06-17 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
KR20220158821A (ko) * 2020-03-27 2022-12-01 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
WO2023004420A1 (en) * 2021-07-22 2023-01-26 Icahn School Of Medicine At Mount Sinai Dual-blockade of il-4 signaling and immune checkpoint proteins for treating cancer
US20230167171A1 (en) * 2021-08-23 2023-06-01 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN118717989A (zh) * 2024-05-27 2024-10-01 中国人民解放军军事科学院军事医学研究院 Il-4r拮抗剂在制备预防和/或治疗流感病毒感染的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181696A1 (en) * 2012-06-05 2013-12-12 The Australian National University Vaccination with interleukin-4 antagonists
WO2014039461A1 (en) * 2012-09-07 2014-03-13 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2014197470A1 (en) * 2013-06-04 2014-12-11 Regeneron Pharmaceuticals, Inc. Mehods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
AU2002360278A1 (en) 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
GB0217920D0 (en) * 2002-04-23 2002-09-11 Aventis Pharm Prod Inc Interleukin-4 Gene Expression inhibitors
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX2010006735A (es) 2007-12-21 2010-09-30 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
EP2414520A2 (en) 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
RS59354B1 (sr) * 2013-06-21 2019-10-31 Sanofi Biotechnology Postupci lečenja nosne polipoze davanjem il-4r antagonista
KR20190062142A (ko) * 2017-11-28 2019-06-05 (주)비티엔 면역 증강 활성을 가지는 아미노산 미네랄 복합체 및 이를 포함하는 식품, 약학 또는 사료용 조성물
US20210361700A1 (en) * 2020-05-22 2021-11-25 Trustees Of Tufts College Nutritional supplement to combat covid-19 and aid vaccination

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181696A1 (en) * 2012-06-05 2013-12-12 The Australian National University Vaccination with interleukin-4 antagonists
WO2014039461A1 (en) * 2012-09-07 2014-03-13 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2014197470A1 (en) * 2013-06-04 2014-12-11 Regeneron Pharmaceuticals, Inc. Mehods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

Also Published As

Publication number Publication date
CN109069625A (zh) 2018-12-21
RU2018133011A3 (cg-RX-API-DMAC10.html) 2020-05-26
EP4420733A2 (en) 2024-08-28
RU2018133011A (ru) 2020-03-19
ZA201805295B (en) 2025-07-30
RU2753869C2 (ru) 2021-08-24
MX2024010676A (es) 2024-09-10
MA44238A (fr) 2018-12-26
AU2017220184A1 (en) 2018-09-13
KR102868264B1 (ko) 2025-10-10
EP3416685B1 (en) 2024-06-26
US20240082380A1 (en) 2024-03-14
AU2024204962A1 (en) 2024-09-26
JP2024112987A (ja) 2024-08-21
MA44238B1 (fr) 2024-07-31
WO2017143270A1 (en) 2017-08-24
EP3416685A1 (en) 2018-12-26
JP7597500B2 (ja) 2024-12-10
MX2018009990A (es) 2018-12-17
JP7813209B2 (ja) 2026-02-12
CA3014202A1 (en) 2017-08-24
ES2983475T3 (es) 2024-10-23
JP2019505554A (ja) 2019-02-28
PT3416685T (pt) 2024-07-25
IL261025A (en) 2018-10-31
US20190321457A1 (en) 2019-10-24
KR20180110089A (ko) 2018-10-08
HUE067673T2 (hu) 2024-11-28
EP4420733A3 (en) 2024-12-11
JP2022185000A (ja) 2022-12-13
US20170239342A1 (en) 2017-08-24
US10314904B2 (en) 2019-06-11
PL3416685T3 (pl) 2024-08-26

Similar Documents

Publication Publication Date Title
US20240082380A1 (en) Methods for Enhancing Efficacy of a Vaccine by Administering an IL-4R Antagonist
TWI633891B (zh) 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
CN105007936B (zh) 无细胞百日咳疫苗
KR20220158821A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
CN115698059A (zh) 使用抗bet v 1抗体治疗过敏的方法
JP6379041B2 (ja) ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対する融合抗原ワクチンおよび組成物
HK40117172A (en) Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
US7572449B2 (en) Vaccine against Yersinia comprising one or two antibodies, one specific for Yersinia pestis F1-antigen and the other one for Yersinia pestis V-antigen
HK40001760B (en) Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
HK40001760A (en) Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
CA3149593A1 (en) Methods of increasing vaccine efficacy
AU2022384263B2 (en) Immunogenic compositions and vaccines in the treatment and prevention of infections
US20260102478A1 (en) Vaccines and Antibodies for the Treatment and Prevention of Neurodegenerative Disorders and Inflammation Related Health Conditions
US20230190906A1 (en) Non-toxic listeriolysin o polypeptides and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)